1 / 31

IHTA Annual Conference

IHTA Annual Conference. The Irish Medicines Board and the regulation of herbal and other medicines. Crowne Plaza Hotel, Dublin Airport - 28 th April 2010. Dr. J.M. Morris Senior Scientific Advisor, IMB. Overview. Introduction to medicines regulation Classification of products as medicines

fuller
Télécharger la présentation

IHTA Annual Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IHTA Annual Conference The Irish Medicines Board and the regulation of herbal and other medicines Crowne Plaza Hotel, Dublin Airport - 28th April 2010 Dr. J.M. Morris Senior Scientific Advisor, IMB

  2. Overview • Introduction to medicines regulation • Classification of products as medicines • Herbal medicines regulatory framework • Homeopathic medicines • Other medicines • Herbal medicines post 2011 • Conclusions and questions

  3. What is a Medicine I • Definition given in Article 1.2 of Directive 2001/83/EC • Revision in Directive 2004/27/EC • IMB guide to definition of a medicinal product for human use based on • Composition • Claim • Presentation • Function

  4. What is a Medicine II Article I of Directive 2001/83/EC, as amended by Directive 2004/27/EC makes changes to the definition of a Medicinal Product. The new definition states that a medicinal product is: • Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or • Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.

  5. Requirements of Medicinal Products • Marketing is controlled by valid authorisation or registration • Protection of consumers • Medicines should be of good quality • Risk of using the product should be reasonable and acceptable in the light of the expected benefit • Demonstrable therapeutic benefit should be anticipated

  6. IMB Guideline “Definition of a Human Medicine” • Non-legally binding advice – definition is in the Directive • Borderline between MP’s and foods, cosmetics, Medical Devices etc. • Adjudication by IMB Classification Committee • Application form and fee • Guideline revised February 2008

  7. Classification Process 1 • Application form on IMB website www.imb.ie • Complete application form in full • Enclose all labels, leaflets, promotional material • Pay attention to websites used to promote products • Application fee €250 (€200 for supplements) • Submit to Classification Committee • Response usually within 28 days

  8. IMB Classification Committee • Multidisciplinary scientific in-house committee • Consists of representatives from Human Medicines, Medical Devices, Compliance Departments • Expertise in medicine, pharmacy, herbal medicine, toxicology, market surveillance and pharmacovigilance , medical devices, cosmetics. • Meets once monthly • Typically 100 applications p.a • Provides a formal response in writing • Decisions can be appealed to ACHM (final)

  9. Classification Process 2 • Open to dialogue – removing a claim or even changing language may alter status • Consultation with other interested parties – e.g. FSAI for food supplements • Two way process – FSAI makes referrals to IMB also • Same active may be present in medicines and foods – e.g, garlic, ginger • Some herbs may be present exclusively in foods i.e. not medicines provided no claims made

  10. Directive on Traditional Herbal Medicinal Products [THMPs] • Must meet pre-defined standards: • - Quality • - Safety • - Traditional Use

  11. Quality • All traditional medicinal products must conform to agreed quality standards as for any other medicinal product • Herbal Medicinal Product Guidelines – HMPWP • 2001/83/EC - where appropriate • New legislation 2004/24/EC • EMA guidelines • European Pharmacopoeia monographs

  12. Efficacy • Full product authorisation application => clinical trial data • Well-established use’ => bibliographic applications • 2004/24/EC -30 years on market, at least 15 in EU for THMP registration

  13. Manufacturing considerations • Good Agricultural Practice [GAP] • Good Manufacturing Practice [GMP]  Manufacturer’s Authorisation • Good Distribution Practice [GDP]  Manufacturer’s/Wholesaler’s Authorisation Third country importation = manufacture

  14. EU/Irish initiatives • European Scientific Co-Operative on Phytotherapy [ESCOP] • Pharmaceutical Committee of the European Union • Herbal Medicinal Products Working Committee [HMPC]/Other Working Parties of the European Medicines Agency • IMB Herbal Medicines Project 2000 - 2002

  15. Homeopathic medicines • Simplified Registration Procedure provided for in 2001/83/EC Chapter 2 • No Hom MP on the market unless it has a MA or SRP • National Rules Scheme adopted in Ireland to allow limited claims on basis of supporting data

  16. Simplified registration • Products administered orally or topically • No specific medicinal claims on labels and literature • Sufficient degree of dilution I in 10,000 or 1/100th of smallest allopathic dose of POM • That is 4x(4d)-2C – or greater dilution (potency)

  17. Documents to be submitted • Details of product and stock • Details of preparation and control of stock(s) • Manufacturing and control file for product • Manufacturing authorisation • Registrations in other MS • Mock-ups of packaging • Product stability data

  18. SRP Products • Exempt from authorisation-no SPC • Exempt from pharmacovigilance • Labelling requirements- Article 69 • Scientific name of stock(s) and dilution level • Name and address of reg holder • “Homeopathic medicinal product without approved therapeutic indication” • No other detail other than as specified

  19. Homeopathic Medicines National Rules Scheme 2010 • Article 16.2 of Directive 2001/83/EC • Implemented by Regulation 11 of SI 540 of 2007 • Product is a homeopathic medicine i.e. prepared from homeopathic stocks using a recognised manufacturing procedure (Pharmacopoeia) • Indication is appropriate • Indication does not need medical diagnosis/intervention • Efficacy established in Ireland • Safety evaluated

  20. Homeopathic National Rules (2) Safety evaluation • Reference to published literature • Oral products derived from food substances • Active used in allopathic medicine dilution of 1 in 10,000 minimum (nmt1/100th therapeutic dose) • 1 part per 10,000 MT

  21. Homeopathic medicines national rules labelling • General labelling requirements of Directive (TitleV) • The product is a homeopathic medicinal product authorised by this procedure • Any evidence of efficacy is not based on clinical trials • Use for symptomatic relief of the condition specified • Consult a Doctor if symptoms persist

  22. Other medicines • Anthroposophic medicines - regulated as medicines when manufactured by a homeopathic (pharmacopoeial) method • “Spagyrics” – methods unlikely to be approved in the pharmacopoeia • HMM Group of Experts at Ph. Eur making good progress

  23. Other medicines 2 • Korsakovian dilutions (k potencies) may be included in pharmacopoeia • Bach flower remedies remain outside legislation • Aromatherapy products not regarded as medicines unless specific claims made

  24. Herbal Medicines post 2011 • Since July 27th 2007 no new THMP can come on the market without PRIOR IMB approval • Existing herbal medicines can remain on the market up to 30/4/2011 • Applications should be received by IMB for by end April 2010 (THMP or WEU) • Products with PA’s can of course continue to be marketed • Few applications received • Problem not restricted to Ireland – same across EU generally

  25. Herbal Medicines post 2011 (2) • Few registrations • Herbal medicines masquerading as foods • “Health claims” vs. medicinal claims • Illegal products • Marketplace availability of herbal products?

  26. Herbal Medicines post 2011 (3) • What can IMB do? • All products need to be registered - as herbal medicines - as food supplements • Registration with IMB or FSAI as appropriate • Documented proof of legal status • No documentation - expect products to be seized

  27. Herbal Medicines Registration • Registration process is feasible and user friendly • IMB is now the primary authority for determining method of sale and supply • No longer bound by the restrictions of prescription legislation • For example Ginkgo biloba could be accepted for THM registration provided suitable indication

  28. Herbal Medicines Registration (2) • IMB aiming constantly to improve clarity of the registration process • Developing lists of herbal substances which can only be considered as medicines • Examples G. biloba A. belladonna H. perforatum • Some of these might be acceptable OTC once registered as THM’s e.g. Ginkgo Valerian

  29. Herbal Medicine Registration (3) • IMB also developing a list of herbal substances acceptable for marketing as foods provided no medicinal claims made • Developing policy in conjunction with - IMB expert Herbal sub-Committee - FSAI - DOHC - Industry • Draft list has approximately 150 entries • Looking forward to further discussion

  30. Conclusion • Need to be aware of the distinction between medicines and foods • IMB Classification process is there to assist • Herbal and homeopathic medicines require registration or authorisation by April 2011 • New national rules scheme introduced for authorisation of homeopathic medicines with limited indications • Herbal medicines registration scheme up and running • “Positive” and “negative” lists being developed to help improve clarity • 30/4/2011 is only 1 year away

  31. Questions Thank you for your attention

More Related